Certa Therapeutics’ investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases
Melbourne, Australia, 4th November 2022 – New research presented today by the University of Michigan reveals ground-breaking results for Certa Therapeutics’ FT011, a novel potential treatment of serious inflammatory and fibrotic diseases. The results in a chronic kidney disease (CKD) study presented at Kidney Week 2022, the annual scientific meeting of the American Society of […]
Certa Therapeutics team to meet with biotech industry leaders during AusBiotech conference in Perth, Australia
Melbourne, Australia, 20 October 2022: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. This year’s AusBiotech Convention will be attended by OccuRx’s Chief Operating Officer, Dr Michelle Bradney. AusBiotech is scheduled to take place 26 – 28 October 2022 in Perth, Western Australia and […]
Certa Therapeutics team to meet with biotech industry leaders during BIO-Europe® conference in Germany
Melbourne, Australia, 17 October 2022: Certa Therapeutics,a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. This year’s BIO-Europe Convention will be attended by Certa Therapeutics Chief Executive Officer, Professor Darren Kelly and Chief Commercial Officer, Dr Gareth Lewis. BIO-Europe® is scheduled to take place 24 – 26 […]
Enrolment completed for Certa Therapeutics’ phase II clinical trial for lead candidate FT011
Melbourne, Australia, 19 July 2022: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases is pleased to announce the completion of patient enrolment in their phase II clinical trial evaluating FT011 as an anti-fibrotic drug for the treatment of systemic sclerosis (SSc). Certa Therapeutics’ novel […]
Certa Therapeutics appoints Dr Gareth Lewis as Chief Commercial Officer
Melbourne, Australia, 01 July 2022: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, is pleased to announce the appointment of Dr Gareth Lewis as Chief Commercial Officer. Dr Lewis joins Certa Therapeutics with over 25 years of R&D experience spanning drug and clinical development, […]
Certa Therapeutics provides promising therapy advancements this World Scleroderma Day
Melbourne, Australia, 29 June 2022: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. Today the world’s scleroderma community comes together to recognise World Scleroderma Day. Certa Therapeutics joins the community in highlighting the need to increase awareness of scleroderma and to advocate for those […]
Certa Therapeutics represented at Biotechnology Innovation Organisation (BIO) International Convention in San Diego
Melbourne, Australia, 13 June 2022: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, announced today that its Chief Executive Officer, Professor Darren Kelly, will be attending the 2022 Biotechnology Innovation Organisation International Convention (BIO). After the past two conventions were held in a virtual […]
Certa Therapeutics to join 40th annual J.P. Morgan Healthcare Conference virtually
Melbourne, Australia, 10 January 2022: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. The Certa Therapeutics team includingits Chief Executive Officer, Professor Darren Kelly, will be participating in the 40th annual J.P. Morgan Healthcare Conference virtually. The conference will once again be convened in […]
First patient enrolled in Certa Therapeutics’ phase II clinical trial for lead candidate FT011
Melbourne, Australia, 18 November 2021: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, enrols first patient in the Phase II clinical trial evaluating FT011 as an anti-fibrotic drug for the treatment of systemic sclerosis (SSc). This phase II trial is a randomised, double blind, […]
Certa Therapeutics appoints Dr Lorna Mitchell as VP, Drug Discovery and Pharmacology
Melbourne, Australia, 11 October 2021: Certa Therapeutic, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. Certa Therapeutics is strengthening their senior leadership team with the appointment of Dr Lorna Mitchell as VP, Drug Discovery and Pharmacology. Certa Therapeutics is a biotechnology company focused on improving lives […]